Tetrahydrocannabinol (Delta 9-THC) Treatment in Chronic Central Neuropathic Pain and Fibromyalgia Patients: Results of a Multicenter Survey
Anesthesiology Research and Practice · 2009
DOI: 10.1155/2009/827290 ↗Kurz gefasst
Fachartikel in der Zeitschrift Anesthesiology Research and Practice, 2009. Verfasst von Janet Weber und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology, Intensive Care, Emergency Medicine and Pain Therapy, Kantonsspital Lucerne, 6000 Lucerne, Switzerland. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0). Gefördert von: Bionorica.
Abstract (Originalsprache)
Central neuropathic pain is difficult to treat, but delta 9-Tetrahydrocannabinol (delta 9-THC) may be a promising therapeutic agent. We administered in 172 patients on average 7.5 mg delta 9-THC over 7 months. Of these, 48 patients prematurely withdrew due to side effects, insufficient analgesia, or expense of therapy. Thus, 124 patients were assessed retrospectively in a multicenter telephone survey. Reported changes in pain intensity, recorded on a numeric rating scale (NRS), Pain Disability Index (PDI), Medical Outcomes Short-Form (SF-12), Quality of Life Impairment by Pain (QLIP), Hospital Anxiety Depression Scale (HADS), and amount of concomitant pain medication were recorded. Psychometric parameters (PDI, SF-12, QLIP, HADS) and pain intensity improved significantly during delta 9-THC treatment. Opioid doses were reduced and patients perceived THC therapy as effective with tolerable side effects. About 25% of the patients, however, did not tolerate the treatment. Therapy success and tolerance can be assessed by a transient delta 9-THC titration and its maintained administration for several weeks. The present survey demonstrates its ameliorating potential for the treatment of chronic pain in central neuropathy and fibromyalgia. A supplemental delta 9-THC treatment as part of a broader pain management plan therefore may represent a promising coanalgesic therapeutic option.
Autor:innen und Institutionen
- Department of Anesthesiology, Intensive Care, Emergency Medicine and Pain Therapy, Kantonsspital Lucerne, 6000 Lucerne, Switzerland.
Förderung
- Bionorica
Zitieren
APA
Weber, J., Schley, M., Casutt, M., Gerber, H., Schuepfer, G., Rukwied, R., Schleinzer, W., Ueberall, M., & Konrad, C. (2009). Tetrahydrocannabinol (Delta 9-THC) Treatment in Chronic Central Neuropathic Pain and Fibromyalgia Patients: Results of a Multicenter Survey. Anesthesiology Research and Practice. https://doi.org/10.1155/2009/827290
Vancouver
Weber J, Schley M, Casutt M, Gerber H, Schuepfer G, Rukwied R, et al. Tetrahydrocannabinol (Delta 9-THC) Treatment in Chronic Central Neuropathic Pain and Fibromyalgia Patients: Results of a Multicenter Survey. Anesthesiology Research and Practice. 2009. doi:10.1155/2009/827290
BibTeX
@article{Weber2009,
author = {Weber, Janet and Schley, Marcus and Casutt, Matthias and Gerber, Helmut and Schuepfer, Guido and Rukwied, Roman and Schleinzer, Wolfgang and Ueberall, Michael and Konrad, Christoph},
title = {Tetrahydrocannabinol (Delta 9-THC) Treatment in Chronic Central Neuropathic Pain and Fibromyalgia Patients: Results of a Multicenter Survey},
journal = {Anesthesiology Research and Practice},
year = {2009},
doi = {10.1155/2009/827290}
}
EUVIMED